key: cord-1000291-wzhpw4sw authors: Wormser, Gary P.; Flatley, Catherine A.; Flatley, Elizabeth M.; White, Patricia A.; Montecalvo, Marisa title: Lack of Convincing Evidence that the Widely Used COVID-19 Vaccines will Produce Herd Immunity date: 2022-02-06 journal: Am J Med DOI: 10.1016/j.amjmed.2022.01.037 sha: 168f9b16d24860fe6cd12d73c91194ce0fb0880d doc_id: 1000291 cord_uid: wzhpw4sw nan far. The remarkable spike in the number of identified cases seems to be occurring primarily among persons who have been vaccinated, which is likely not surprising since this group comprises the majority of the adult population. One illustrative example of the remarkable potential for the spread of SARS-CoV-2 despite vaccination is as follows. In mid-December 2021 a group of 30 graduate students, ages 29-45 years, attended their first in-person class in more than four weeks. During the 8 hour class the students presented their research projects. Vaccination was required of all students prior to attendance, and all had to have tested negative for SARS-CoV-2 on a saliva sample within 24 hours before arriving at the classroom. Five teaching staff members were also present for the duration of the 8 hour class, as well as approximately five student mentors who attended for up to five hours of the class, and approximately 10 student spouses who each attended for about one hour. Vaccination was required of all the non-student attendees, but it is unknown whether they were also required to have a negative COVID-19 test prior to attending. All attendees wore a face mask during the entire time spent in the classroom except while eating; they also did not wear masks while attending a party at another location that took place after the class was finished. This party included additional student family members. Seven of the 30 students developed mild symptoms consistent with COVID-19 within 48-72 hours of attending the class, and 6 tested positive for COVID-19 (i.e., 20% of the students developed COVID-19). Three other students developed symptoms between days 5 and 10 following the class and also tested positive for COVID-19. The SARS-CoV-2 variant causing these infections was not determined. United Kingdom Health Security Agency has suggested that protection against symptomatic disease at 25 weeks after two vaccine doses might be less than 10% for the omicron variant, compared with 40% for the delta variant [12] . This reinforces the concept of booster dosing for recipients of an mRNA vaccine [8, 9] , although the exact efficacy of booster doses to prevent omicron infection has not as yet been established. Future studies might also attempt to correlate the level of the immune response to the level of protection observed clinically, allowing a more precise determination of who in the future might require additional vaccine doses and when. SARS-CoV-2 strain differences that impact contagiousness have a substantive impact on the proportion of a population group that need to be fully protected to achieve herd immunity. At the beginning of the pandemic the reproductive number was estimated to be 2.5 [12] , implying that herd immunity could be achieved if only approximately 60% of the population had immunity (natural or vaccine derived). Estimates for the reproductive number for the more contagious delta variant are close to 7 [12] , implying that approximately 85% of the population would need to be immune to infection to achieve herd immunity, rising to approximately 90% for the omicron variant, whose estimated reproductive number could be as high as 10 [12] . Ninety percent of the population achieving long lasting immunity seems rather unrealistic with the vaccines currently available, raising concerns that herd immunity is not a realistic answer to ending this pandemic. However, new approaches to vaccine development are in progress, which might impact this in a more favorable manner [13] . In addition, rapid spread of a minimally virulent but highly contagious strain of SARS-CoV-2 might per se also promote widespread immunity [14] , including for those who prefer not to be vaccinated. Natural infection with SARS-CoV-2 has been shown to be highly protective against a recurrence of symptomatic infection, with an efficacy rate of 84.5% in one study (95% CI of 77.9-89.1%) [15] . Studies of patients during the SARS pandemic in 2003 found that an antibody response from this infection persisted for 2 years [15] . Infections with the seasonal strains of coronavirus, however, do not lead to the development of long-term protection [15] . Whether the recent and rapid spread of omicron might promote widespread immunity against a future infection caused by a different strain of SARS-CoV-2 is an open question, but unfortunately it appears that the omicron variant does not invariably cause a benign infection [16] . symptomatic COVID-19 infections falls over relatively short periods of time. Efficacy is also highly dependent on the particular variant of SARS-CoV-2 that a person is exposed to. While these vaccines have been successful in reducing hospitalization and death, the likelihood of developing herd immunity using the currently available vaccines appears to be low. Dr. Wormser reports receiving research grants from the Institute for Systems Biology and Pfizer, Inc. He has been an expert witness in malpractice cases involving Lyme disease; and is an unpaid board member of the non-profit American Lyme Disease Foundation. Other authors: None. All authors have participated in the preparation of the manuscript. Covid-19 vaccine effectiveness in New York State Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase Evaluating the long-term efficacy of coronavirus disease 2019 (COVID-19) vaccines SARS-CoV-2 transmission from people without COVID-19 symptoms Booster doses of mRNA-based COVID-19 vaccines for all adults SARS-CoV-2 vaccine protection and deaths among US veterans during 2021 Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression Omicron variant and booster COVID-19 vaccine Safety, tolerability, and immunogenicity of an aerosolized adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomized phase 1 clinical trial Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques Reinfection rates among patients who previously tested positive for Coronavirus disease 2019: A retrospective cohort study How severe are omicron infections? The authors thank Joan Wormser for assistance. This manuscript is dedicated to the memory of Dr. Stephen Seligman, a respected leader in the field of infectious diseases.